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the patients with high blood-sugar levels visit doctors retrospectively, its monthly 
medical cost would have been 4.12 million yen lower now, which represents 412 
yen a month per member.
PDB21
CliniCal EffiCaCy anD Costs of insulin analoguE ComParED to 
Human insulin in PatiEnts WitH DiaBEtEs: rEsults from a tErtiary 
HosPital in BEijing
Guan X1, Xu Z1, Hu C2, Wu J3
1The 306th Hospital of PLA, Beijing, China, 2Peking University Health Science Centre, Beijing, 
China, 3Pharmacoeconomics Committee of Chinese Pharmaceutical Association, Beijing, China
Objectives: This study aims to compare clinical efficacy and costs between insulin 
analogue and human insulin in treatment of patients with diabetes in a tertiary hos-
pital in Beijing. MethOds: Data were extracted from inpatient electronic patient 
records in HIS system in a tertiary hospital in Beijing during the period between 
Aug 2011 and Nov 2013. Inclusion criteria: main admitting diagnoses were type I 
diabetes or type II diabetes; insulin analogue or human insulin were used during 
hospital stay. Exclusion criteria: combination use of insulin analogue and human 
insulin. Fasting blood-glucose (FPG) before breakfast was used as efficacy index 
while total inpatient expenditure was used as cost index. Unfortunately, HbA1c 
level was unavailable to this study. Student-t test and Chi-square test were con-
ducted using SPSS 20.0. Results: Insulin analogue (n= 50) and human insulin 
(n= 49) cohort had comparable male (68% vs 49%, P= 0.055), age (50 vs 57, P= 0.008), 
and baseline clinical characteristics (length of stay 10 vs 11, P= 0.133; baseline FPG 
8.73mmol/L vs 8.44mmol/L, P= 0.630). At the point of discharge, FPG before breakfast 
was dropped to 6.39mmol/L vs 7.13mmol/L (P= 0.025) in insulin analogue and human 
insulin cohort, respectively. The total medical costs were CNY 11,305 vs CNY 10,693 
(P= 0.577), and total drug costs were CNY 5,198 vs CNY 4,199 (P= 0.186), in insulin 
analogue and human insulin cohort, respectively. cOnclusiOns: Insulin analogue 
treated patients experienced significantly greater reductions in FPG before breakfast 
compared to human insulin treated patients, while total inpatient expenditure and 
drug costs showed no significant difference between the two cohorts. Should data 
permits, HbA1c data should be included in further analysis in the future.
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Objectives: To evaluate the cost, cost-effectiveness and cost-benefit of clinical 
pharmacy service for diabetic patients on view of hospital. MethOds: A prospec-
tive study was conducted at a provincial hospital in Sichuan, China. Inpatients 
with a diagnosis of diabetes were enrolled in the study during 2010.03 -2011.06. 
Patients were divided into intervention group(121) and control group(122) randomly 
when admitted. Intervention group equipped a clinical pharmacist providing clini-
cal pharmacy services during therapy, the control group took routinely pharmacy 
service. The times of avoiding medicine errors were counted as effectiveness, the 
saving of patients’ expense was calculated as benefit. The cost was calculated by 
routine/clinical pharmacy service spending. Cost-effectiveness and cost-benefit 
analysis were conducted. Results: The average length of stay was 13.82 days in 
intervention group and 14.79 days in control group(P> 0.05). Average 337 minutes(5.6 
hours) was spent in daily clinical pharmacy services in intervention group. The cost 
of routine pharmacy service in control group was 729.05$(daily salary* average stay 
length of patients), while clinical pharmacy services cost in intervention group was 
estimated as 1175.82$(routine pharmacy service cost+ training cost+ clinical phar-
macy services cost), 446.77$ more than routine(theoretically, didn’t actually happen). 
The average percentage of avoiding medicine errors was 64.19% in intervention 
groups and 3.54% in control group(total suggestion times for adjusting drug schemes 
/total medical orders), accordingly the cost-effectiveness of avoiding medicines 
errors(C/E) in intervention group was 18.32 while 209.95 in control group. The aver-
age admission expense was 1703.80$ in intervention group and 1959.50$ in control 
group(P< 0.05), so average saving expense of patients under clinical pharmacy inter-
vention was 255.69$. Comparing with the extra possible input of providing clinical 
pharmacy service, the net benefit was -191.08$. cOnclusiOns: Clinical pharmacy 
service do play a significant role in avoiding medicine errors and reducing patient 
expenses, if didn’t consider the time and labor cost of clinical pharmacist.
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Objectives: To evaluate the long-term economic and health outcomes associated 
with once daily liraglutide 1.2 mg, the most frequently prescribed dosage in China, 
versus twice daily exenatide 10 μ g prescribed according to National Institute for 
Health and Clinical Excellence recommendations in clinical practice in patients with 
Type 2 Diabetes Mellitus (T2DM). MethOds: A published and validated computer 
simulation model (CORE Diabetes Model) was used to make the projection of 30-year 
long-term economic and health outcomes. Simulated cohorts and treatment effects 
were derived from results of a retrospective chart audit with a median follow-up of 
48 weeks including 256 patients receiving liraglutide and 148 receiving exenatide. 
Treatment costs were derived from drug retail prices in Chinese market. The dia-
betes management and complication costs were obtained from Chinese published 
data. Projections were made from a societal perspective with an annual discounting 
rate of 3%. One-way sensitivity analyses were performed. Results: Long term pro-
jections demonstrated that compared with exenatide, liraglutide 1.2 mg was asso-
ciated with lower cumulative incidences of diabetes complications and improved 
Objectives: To explore medical expenditure and its impact for people with diabetes 
covered by Urban Employee Basic Medical Insurance for Hebei Provincial Institutes 
(UEBMIHPI). MethOds: People diagnosed with “diabetes” were identified from 
UEBMIHPI claims database during Dec 30th, 2010 and Dec 25th, 2011. The Sum_All 
Medical method was used for expenditure estimation. Descriptive analyses were 
conducted using EXCEL 2010. Results: During Dec 30th, 2010 and Dec 25th, 2011, 
the UEBMIHPI database recorded claims data of 110256 patients, including 7944 with 
diabetes (7.21% of all patients), among which 7421 had outpatient records (7.24% 
of all outpatients) and 2964 had inpatient records (12.16% of all inpatients). 63.28% 
were male and 79.51% were 50 years of age or older. Mean number of outpatient 
visits was 14.04 for people with diabetes, in comparison with 4.12 for outpatient 
with other diseases. Outpatient treatment cost was CNY 9332.52/person and CNY 
724.99/visit, of which 30.59% were out-of-pocket money. For those who had used 
inpatient services, annual inpatient admissions were 1.67 times/person and the cost 
was CNY 23494.63/person and CNY 14109.20/hospital stay. Over 60% hospitaliza-
tions happened in tertiary hospitals. People with diabetes consumed 21.59% (CNY 
139million) of total medical expenditure. Only CNY 21 million (15.42%) was spent 
on anti-glycaemic treatments, the cost of OAD, insulin, insulin pump and Chinese 
traditional drugs accounted for 52.27%, 40.75%, 2.62% and 4.36% respectively. People 
with diabetes who received diagnoses or treatments for diabetic complications 
consumed more health care resources (physician visit, medical expenditure/person 
and medical expenditure/visit) than others. cOnclusiOns: As one of the major 
chronic diseases, diabetes consumed great health care resources in Hebei. Majority 
of direct medical expenditures were spent on treating diabetes-related diseases. 
Perhaps to reduce risks of diabetes complications by promoting early diagnosis, 
early treatment, rational drug utilization and disease control is the way to save 
health care and social resources.
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Objectives: To collate published evidence evaluating economic implications of 
chronic renal disease (CRD) with and without co-morbid diabetes mellitus in China 
(post-2005). MethOds: A systematic search of electronic databases (Embase® and 
MEDLINE®) was conducted from January 2005 to March 2014 to identify economic 
studies in English evaluating CRD with and without co-morbid diabetes mellitus in 
China. Results: Five studies (all cost of illness, CRD [n= 3] and CRD with co-morbid 
diabetes [n= 2]) of 134 citations retrieved, met pre-defined inclusion criteria. In 2012, 
total cost/patient for stage-3/4 CRD was Chinese Yuan (CYN) 34205 with 97.75% 
being direct cost, while for stage-5 CRD the corresponding values were CYN128231 
and 82.3%, respectively (Wu 2013). In the study by Zhang and colleagues, patients 
undergoing haemodialysis (HD) incurred 16% higher costs relative to those undergo-
ing peritoneal dialysis (PD) in 2010 (p= 0.01). Further, patients with comorbid diabe-
tes incurred higher total costs compared to their CRD alone counterparts (p= 0.03) 
(Zhang 2012). Among patients with CRD in northwest China observed between 
March 2007 and February 2008, the first, second, and third year renal transplant 
(RT)/HD costs were CYN201674/CYN94136, CYN71746/CYN87765, and CYN66851/
CYN86987, respectively indicating higher efficacy and lower costs of RT than HD 
from second year onwards (Xiaoming 2012). These findings were consistent with 
those reported in another study; in 2011 the direct cost of diabetes-associated renal 
failure with HD/PD was CYN72761.17/CYN470764.77 and RT was CYN218508.075 
(Zheng 2012). Among diabetic patients with comorbid CRD, direct cost in 2007 was 
CYN1308.07 million, while corresponding cost projected in 2030 increased two-fold 
to CYN2351.60 million (Wang 2009). cOnclusiOns: CRD consumes a large portion 
of health care expenditures (with direct medical cost being main cost driver) and 
is projected to exert heavy burden on health budget in future as well. Additionally, 
patients with comorbid diabetes incurred higher costs relative to their CRD alone 
counterparts.
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Objectives: We define patients who have not consulted doctors to treat their 
diabetes, while they have learned their blood-sugar levels are high through health 
check-up, as untreated-diabetes patients. Our research objective is to calculate 
using real world data how much lower the medical cost would be if the untreated-
diabetes patients visit doctors in response to suggestions to do, which represents 
the cost reduction of cost-effectiveness analysis. MethOds: We used the data 
of Japan Medical Data Center (JMDC), which provides health insurance claims 
data with linked health check-up data of 1.7 million members from health insur-
ance societies in Japan. Results: It is estimated there are 71 untreated-diabetes 
patients in a virtual (yet supposed-to-be typical according to the JMDC data) health 
insurance society with 10,000 members. And 16% of them would visit doctors 
within 3 months, while remaining 84% would leave their conditions as they are 
for averagely 40 months knowing that their blood-sugar levels are high. It is nec-
essary to advise untreated-diabetes patients to visit doctors for treatment. Such 
advices should be able to start their diabetes treatment in early stages and prevent 
them from future complicating diseases. According to our calculation, the medical 
cost after its diagnosis would increase by 1.1% without aging factors by leaving 
their untreated-diabetes conditions for one month. cOnclusiOns: If the virtual 
health insurance society had all the existing 71 untreated-diabetes patients visit 
doctors right now, their monthly medical cost would be 0.37 million yen lower 
against the amount they had to pay in the future (averagely in 20 months) if they 
continue to avoid visiting, which represents 37 yen a month per member, and all 
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fees, and costs for diagostic procedures, hospitalization, treatment costs for adverse 
drug reactions (ADRs) and other costs arising from medical intervention among the 
sole surgical treatment group (35 cases), the group of preoperative treatment with 
lanreotide (36 cases), and the group of preoperative treatment with octreotide (18 
cases). Results: Based on the good compatibility of tumor size, postoperative aver-
age length of stay in hospital, biochemical indicators (IGF-I, GH ) among the three 
groups, there was no statistical difference in the clinical effectiveness (x2 = 2.81, 
P = 0.250). As to the total medical costs per case, both octreotide group and lanreo-
tide group were higher than the sole operation group with a statistical significant 
(F = 21.05, P = 0.000), and the lanreotide group (70521 ± 25677 Yuan) was lower than 
the octreotide group (80283 ± 21486 Yuan) with the Median non-parametric test (P = 
0.037). The sensitivity analysis showed that the cost advantage of lanreotide relected 
in prolonging the length of the preoperative treatment. cOnclusiOns: According 
to the data of direct medical costs from the sampling hospital in Shanghai, lanreo-
tide has more cost advantage comparing with octreotide.
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Objectives: Metformin is the first-line oral hypoglycemic agent for type 2 diabe-
tes mellitus (T2DM) per international guideline with proven efficacy, safety and 
cost-effectiveness. However, little information exists comparing it with acarbose. 
This study aims to ascertain both the effectiveness and cost-effectiveness of these 
two extensively-adopted agents in treatment of T2DM. MethOds: Randomised 
Controlled Trials comparing metformin and acarbose with placebo and sulfony-
lureas were systematically reviewed from Chinese (CNKI) and English (PubMed) 
literatures. Meta-analysis and Bucher-method-based indirect comparisons were 
conducted to compare the hypoglycemic-effects of metformin and acarbose directly 
and indirectly by using common comparators. The weighted-mean-difference and 
95%CIs were calculated. Cost-minimization analysis was performed from the per-
spective of medical insurance. Common clinical scenarios were set according to 
clinical practices and physicians’ prescribing behaviors in China, which could mirror 
real-life cost data. Results: The direct comparison (8 trials) indicated treatment 
difference between metformin and acarbose for reduction of HbA1c was -0.06% (95% 
CI, -0.32 to 0.20). In the indirect comparisons (67 trials), using placebo and sulphony-
lureas as common comparators, metformin achieved significant HbA1c reduction 
than acarbose, by -0.38% (95% CI, -0.736 to -0.024) and -0.34% (95% CI, -0.651 to -0.029) 
respectively. Cost-minimization analysis was conducted on the assumption that 
these two agents had same hypoglycemic effects. In the first two scenarios, acarbose 
was assumed to titrate from 50mg/day up to 150 mg/day (weight< 60kg) or 300mg/
day (weight> = 60kg) as usual max-dose, and the annual-costs were ¥2,656.36 and 
¥5,208.84. In the last two scenarios, metformin was assumed to titrate from 500mg/
day up to 1500mg/day or 2000mg/day, while the annual-costs were ¥1,568.04 and 
¥2,070.28. Metformin would achieve cost-savings by 22.06% to 69.90% than acarbose, 
and sensitive analysis demonstrated its robustness. cOnclusiOns: Findings from 
this study are consistent with previous studies of metformin in other countries. 
Metformin has significant hypoglycemic-effects and low costs in China.
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Objectives: The complications for the use of both concentrations U100 insu-
lin (100 units [U]/ml) and U40 insulin (40 units [U]/ml) were not studied in Egypt. 
The objective of the study was a cost minimization analysis of the two available 
concentrations for U100 insulin and U40 insulin from the health care system’s 
perspective. MethOds: A decision analysis model of patients with diabetes was 
constructed. Prevalence rate of diabetes in Egypt and complication rates of both the 
use of U100 insulin and U40 insulin were obtained from international published 
sources. Direct medical costs were derived from the Ministry of Health tender list. 
All costs were reported in Egyptian pounds of the financial year 2014. Deterministic 
sensitivity analysis was conducted. Results: Total expected costs for U100 insulin 
and U40 insulin were LE 262,218,165 and LE 345,582,844 respectively. In the base case, 
the use of U100 insulin displayed a cost advantage over U40 insulin for the treatment 
of diabetic patients with a minimal percent of complications. The model resulted 
in total savings of LE 83,364,678 in favor of Insulin 100 units. Sensitivity analyses 
determined that the cost of U100 insulin and U40 insulin had the potential to impact 
the base case model. cOnclusiOns: This cost-minimization study illustrates that 
Conversion to U100 insulin would result in lower overall treatment costs in patients 
with diabetes from the health care system’s perspective. An intensive information 
campaign providing detailed advice for patients, physicians and pharmacists is 
essential for the prevention of medication errors and reduction of overall costs.
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Objectives: Cost utility analyses (CUA) of diabetes treatments have tradition-
ally been performed using HbA1c as a surrogate endpoint for diabetes complica-
tions and mortality. This study introduces a novel approach to CUA modelling of 
diabetes whereby blood sugar control as measured by HbA1c is used to directly 
long term health outcomes for patients with T2DM. Compared with exenatide, the 
cumulative incidences of eye disease, renal disease, stroke event, and myocardial 
infarction event with liraglutide were reduced by 1.657%, 1.45%, 0.639% and 1.392% 
respectively. Liraglutide 1.2mg was associated with improvements in life expec-
tancy of 0.109 years and 0.092 quality-adjusted life years (QALYs) versus exenatide. 
The costs of complications were reduced by 1,769 CNY (111,567 vs 113,336), result-
ing in a total direct medical cost saving of 7,626 CNY. These results indicated that 
liraglutide 1.2 mg was cost saving approach in comparison with exenatide. 
Sensitivity analyses demonstrated the robustness of results. cOnclusiOns: The 
treatment of liraglutide 1.2 mg improved patient health and economic outcomes 
versus exenatide, and was a dominant treatment approach for T2DM patients in 
clinical practice.
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Objectives: To evaluate long-term cost-effectiveness of switching to biphasic 
human insulin 30 [Isophane Protamine Biosynthetic Human Insulin Injection (pre-
mixed30R)] in people with type 2 diabetes (T2DM) poorly controlled with oral anti-
diabetic drugs (OAD) in China. MethOds: The validated IMS CORE Diabetes Model 
(V8.5) was used to project long-term life years, quality-adjusted life years (QALYs) 
and costs over 30 years. Patients’ baseline demographics and treatment effects were 
based on the published 8-week observational study in China. Hba1c deceased from 
10.18% to 7.57 after initiating biphasic human insulin 30 (±metformin) for people 
uncontrolled with sulfonylureas and metformin, and hypoglycaemic events was 
0.80 per patient-year during the study period. Treatment costs were calculated by 
multiplying retail prices in China and dosage used in the trial. Management and 
complication costs were obtained from published data in 2011 and inflated to 2012 
with consumer price index. An annual discounting rate of 3% was used for both costs 
and health outcomes. One-way sensitivity analyses were conducted. Results: It 
was projected switching to biphasic human insulin 30 improved life expectancy by 
0.655 years (13.113 vs. 12.458) and quality-adjusted life-years by 0.609QALYs (9.270vs. 
8.661) per patient. Biphasic human insulin 30 decreased cumulative incidence of 
most diabetes-related complications, and was associated with decreased manage-
ment and complication costs of -6787 RMB (147066 vs. 153853).Although offset by 
higher direct treatment cost (54671 vs. 54366), switching to biphasic human insulin 
30 was projected to lower total direct medical cost of -6482 RMB lower (201737 vs. 
208219). Sensitivity analyses demonstrate robustness of result. cOnclusiOns: 
Initiating biphasic human insulin 30 for OAD failures was projected to improve life 
expectancy and reduce lifetime direct medical costs. Switching to biphasic human 
insulin 30 was a cost-saving treatment option for people with T2DM insufficiently 
controlled with OADs in China.
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Objectives: Systematically review published literatures comparing the cost-effec-
tiveness of insulin analogs versus human insulin [NPH], by which provide evidence 
for relevant health decision-making and clinical treatment. MethOds: earch lit-
eratures about the economic evaluation of insulin analogs versus human insulin 
in Chinese and English literature database. Basic information, data sources and 
results of included studies were analyzed and reviewed. Results: Twenty seven 
studies in 16 published papers carried out in Canada, USA, European, Australia and 
China were included in the review. The results in the studies were significantly 
inconsistent, which was perhaps mainly due to the different data source, model 
selection, time horizon and hypothesis. However, the public health institutes in 
Canada, UK, Germany and Australia had reported highly suspiciousness on the 
cost-effectiveness of insulin analogs for diabetes patients, especially for type II dia-
betes. cOnclusiOns: In lack of powerful evidence, it has not reached an agreement 
about the cost-effectiveness of insulin analogs and human insulin for diabetes. In 
countries like Canada, UK, Germany and Australia, the reimbursement policies on 
insulin analogs were recommended with cautious. As China is a developing country, 
diabetes patients should select appropriate regimes even more cautiously accord-
ing to local health care system, personal disease characteristics and affordability. 
Future studies, comparing the cost-effectiveness of insulin analogs with human 
insulin, should be conducted with longer time horizon and be based on updated 
and more reliable clinical data.
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Objectives:  To carry on a pharmacoeconomic evaluation study on preoperative 
treatment of acromegaly patients with somatostatin analogues (lanreotide and 
octreotide) in Shanghai. MethOds: Through a retrospective clinical study with 
cost minimization analysis (CMA) from a perspective of health service providers, to 
collect 89 acromegaly patients’ medical records in a sampling hospital from January 
1, 2009 through June 30, 2013, then comparing the clinical effectiveness (the overall 
cure rate based on IGF-I values returned into normal range after 3 months of post-
operation) and the direct medical costs including drug cost, medical consultation 
